Featured Press Releases

At the Longhorn Vaccines and Diagnostics Presents Compelling Data on the LHNVD-303 Vaccine for Sepsis Linked to Bacterial Infections

At the Longhorn Vaccines and Diagnostics Presents Compelling Data on the LHNVD-303 Vaccine for Sepsis Linked to Bacterial Infections

Beacon Therapeutics has been granted FDA Regenerative Medicine Advanced Therapy (RMAT) designation for laru-zova (AGTC-501)

Beacon Therapeutics has been granted FDA Regenerative Medicine Advanced Therapy (RMAT) designation for laru-zova (AGTC-501)

  • 24 Jan 2025

Beacon Therapeutics Holdings Limited a leading ophthalmic gene therapy company with a mission to...

Setting a New Standard for End-to-End Traceability and Data Integrity, Waters Enhances Alliance iS HPLC System Software.

Setting a New Standard for End-to-End Traceability and Data Integrity, Waters Enhances Alliance iS HPLC System Software.

Octapharma Announces Availability of Balfaxar® For Warfarin Reversal in Urgent Surgery & Invasive Procedures

Octapharma Announces Availability of Balfaxar® For Warfarin Reversal in Urgent Surgery & Invasive Procedures

IRBM Expands Functional Genomics Platform for Early Drug Discovery

IRBM Expands Functional Genomics Platform for Early Drug Discovery

New long-term data confirms TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to block joint damage in active psoriatic arthritis

New long-term data confirms TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to block joint damage in active psoriatic arthritis

VahatiCor Closes Oversubscribed Series B Financing to Speed Up A-FLUX® Development for Coronary Microvascular Dysfunction

VahatiCor Closes Oversubscribed Series B Financing to Speed Up A-FLUX® Development for Coronary Microvascular Dysfunction

  • Intuitive Ventures
  • 19 Nov 2025
FDA Approves Arrowhead Pharmaceuticals’ REDEMPLO® (plozasiran) for Reducing Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).

FDA Approves Arrowhead Pharmaceuticals’ REDEMPLO® (plozasiran) for Reducing Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).

  • Arrowhead Pharmaceuticals, Inc.
  • 19 Nov 2025
Emulate, in Partnership with FUJIFILM Cellular Dynamics, Launches Brain-Chip R1 to Advance Neurological Drug Development

Emulate, in Partnership with FUJIFILM Cellular Dynamics, Launches Brain-Chip R1 to Advance Neurological Drug Development

  • Emulate, Inc. and FUJIFILM Cellular Dynamics
  • 18 Nov 2025
Jazz Pharmaceuticals presents new clinical and translational data for Modeyso™ (dordaviprone) in H3 K27M-mutant diffuse midline glioma at SNO 2025

Jazz Pharmaceuticals presents new clinical and translational data for Modeyso™ (dordaviprone) in H3 K27M-mutant diffuse midline glioma at SNO 2025

  • Jazz Pharmaceuticals plc
  • 17 Nov 2025
New long-term data confirms TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to block joint damage in active psoriatic arthritis

New long-term data confirms TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to block joint damage in active psoriatic arthritis

  • Johnson & Johnson
  • 17 Nov 2025
Marius Pharmaceuticals has expanded its global footprint with Health Canada’s approval of KYZATREX® (testosterone undecanoate) CIII capsules

Marius Pharmaceuticals has expanded its global footprint with Health Canada’s approval of KYZATREX® (testosterone undecanoate) CIII capsules

  • Marius Pharmaceuticals LLC
  • 13 Nov 2025
World Drug Delivery Summit 2025
The Digital Pharma Advances Conference 2026

Most Popular
November   2025
M T W T F S S
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.